- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07949695
Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer
An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer
This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer.
Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety.
A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yongsheng Jia
- Numéro de téléphone: +86-18622199359
- E-mail: yongshengjia@tjmuch.com
Lieux d'étude
-
-
-
Tianjin, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute and Hospital
-
Contact:
- Yongsheng Jia
- Numéro de téléphone: +86-18622199359
- E-mail: yongshengjia@tjmuch.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged ≥18 and ≤70 years old.
- Histopathologically confirmed invasive breast cancer; no prior systemic anti-tumor therapy for breast cancer.
- Histopathologically confirmed HR-positive (ER >1%) and HER2-low breast cancer. HER2-low is defined as IHC 1+ or IHC 2+ with ISH-negative.
- Ki-67 proliferation index ≥30%.
- Stage II-III breast cancer per the 8th edition AJCC TNM staging criteria (cT2 N1-2 M0, or T3-4 N0-2 cM0).
- At least one measurable target lesion according to RECIST Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Female participants may be pre-menopausal, peri-menopausal or post-menopausal. Post-menopause is defined according to CSCO Breast Cancer Guidelines as any one of the following:
Bilateral oophorectomy;
- Age ≥ 60 years;
- Age < 60 years with spontaneous amenorrhea for ≥12 months; no chemotherapy, tamoxifen, toremifene or ovarian function suppression in the past 12 months, and post-menopausal levels of FSH and estradiol;
- Age < 60 years receiving tamoxifen or toremifene, with post-menopausal FSH and estradiol levels documented on two consecutive tests.
9、Adequate organ function (no blood product or growth-factor-supported correction within 14 days prior to first study drug administration):
- Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L.
- Hepatic and renal function: Albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen and serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
- Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO).
- Electrocardiogram: QTcF (Fridericia-corrected QT interval) ≤ 470 ms for female subjects.
10、For pre-menopausal women of child-bearing potential: serum pregnancy test negative within 7 days before initiation of study treatment; non-lactating. All enrolled female participants must use adequate barrier contraception throughout treatment and for 6 months after completion of study treatment.
11、Voluntarily agrees to participate, provides written informed consent, demonstrates good compliance and is willing to complete all study-related visits and procedures.
Exclusion Criteria:
- Breast cancer without histopathological confirmation.
- Bilateral breast cancer, inflammatory breast cancer or occult breast cancer.
- Prior anti-neoplastic therapy of any modality (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.). Definitive radiotherapy received within 4 weeks before first study drug dose, or palliative radiotherapy received within 2 weeks before first study drug dose.
- Concurrent receipt of any other anti-tumor therapy.
- History of other malignancies within the past 5 years, except for cured basal-cell skin carcinoma and carcinoma in situ of cervix.
- Participation in another investigational-drug clinical trial within 4 weeks prior to enrollment.
- Received immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone equivalent) within 2 weeks before first study drug administration; nasal or inhaled corticosteroids are permitted.
- Administration of live or attenuated vaccines within 4 weeks prior to first study drug dose.
- Major surgery unrelated to breast cancer within 4 weeks before first study drug dose, or incomplete recovery from such surgery.
- Active autoimmune disease, or history of autoimmune disease prone to relapse (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; hypothyroidism controlled solely by hormone-replacement therapy is allowed). Subjects with skin disorders not requiring systemic therapy (vitiligo, psoriasis, alopecia), insulin-controlled type 1 diabetes, or childhood-onset asthma fully resolved without adult-time intervention may be enrolled. Asthma requiring bronchodilator intervention is excluded.
- History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency, or history of organ transplantation.
- Uncontrolled or clinically significant cardiovascular-cerebrovascular disease. Any of the following occurring within 6 months prior to first dose: NYHA class III-IV congestive heart failure, myocardial infarction, cerebral infarction (lacunar infarction excluded), pulmonary embolism, unstable angina; arrhythmias requiring treatment at screening; primary cardiomyopathy (dilated, hypertrophic, arrhythmogenic right-ventricular, restrictive or unclassified cardiomyopathy); clinically significant history of QTc prolongation; second-degree type-II or third-degree atrioventricular block; female QTcF > 470 ms; atrial fibrillation (EHRA grade ≥ 2b); uncontrolled hypertension judged by investigator to make subject ineligible.
- Known or suspected interstitial pneumonia; moderate-to-severe pulmonary disease impairing respiratory function within 3 months before first dose that may confound detection/management of drug-related pulmonary toxicity, including idiopathic pulmonary fibrosis, organizing pneumonia / bronchiolitis obliterans, pulmonary embolism, severe asthma, severe COPD, obstructive/restrictive lung disease; autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (e.g. rheumatoid arthritis, Sjögren syndrome, sarcoidosis); prior total pneumonectomy.
- Active hepatitis B (HBsAg-positive with HBV-DNA ≥ 500 IU/mL), hepatitis C (HCV-antibody-positive with HCV-RNA above upper limit of normal), liver cirrhosis; severe infection requiring antibiotics, antiviral or antifungal therapy.
- Known inherited or acquired bleeding or thrombotic diathesis (e.g. hemophilia, coagulopathy).
- Known hypersensitivity or contraindications to study drugs or their excipients.
- Pregnant or lactating women; women of child-bearing potential with positive baseline serum pregnancy test; women of child-bearing potential unwilling to use effective contraception throughout the study period.
- Concomitant medical conditions that, in the investigator's judgment, would endanger subject safety or prevent completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection).
- Documented history of neurological or psychiatric disorders including epilepsy or dementia; or any other condition rendering the subject unsuitable for the study in the investigator's opinion.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Trastuzumab Rezetecan plus Toripalimab and Endocrine Therapy Neoadjuvant Treatment
|
Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pathological Complete Response Rate (pCR, ypT0/isN0)
Délai: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients achieving pathological complete response (pCR, defined as ypT0/isN0) in breast and axillary lymph nodes after neoadjuvant therapy, assessed by central pathology review after surgery |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
Percentage of patients with confirmed objective response (CR or PR) assessed by investigator according to RECIST criteria. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Residual Cancer Burden (RCB)
Délai: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
RCB class and continuous RCB score determined from surgical specimens after neoadjuvant treatment. |
At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
|
|
Event-Free Survival (EFS)
Délai: Up to 3 years after surgery
|
Time from enrollment to first occurrence of invasive breast cancer recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever comes first. |
Up to 3 years after surgery
|
|
Overall Survival (OS)
Délai: Up to 5 years after surgery
|
Time from enrollment to death from any cause. |
Up to 5 years after surgery
|
|
Safety
Délai: From start of study treatment up to 30 days after last dose of study drugs
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded per CTCAE. |
From start of study treatment up to 30 days after last dose of study drugs
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Immune biomarkers (sTIL, PD-L1, etc.)
Délai: Baseline and at surgery
|
Assessment of immune biomarkers including stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression in baseline tumor samples and post-treatment surgical specimens. |
Baseline and at surgery
|
|
Ki-67 expression
Délai: Baseline and at surgery
|
Change in Ki-67 proliferation index between baseline biopsy and surgical specimens after neoadjuvant therapy. |
Baseline and at surgery
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- E20261415
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .